Commentary: Risks of doing as the Romans doBMJ 2009; 338 doi: https://doi.org/10.1136/bmj.b1107 (Published 31 March 2009) Cite this as: BMJ 2009;338:b1107
- Michael Tremblay, partner
- 1Tremblay Consulting, Brabourne Lees, Ashford, Kent TN25 6RJ
Garattini and Chalmers (doi:10.1136/bmj.b1025) make four suggestions to improve the evaluation of drugs—involve patients in establishing research priorities, improve the transparency of drug evaluations and studies, fund independent drug evaluations, and require evidence that new drugs have added clinical value. Although controversial, many of their proposals would benefit patients. However, their suggestion to follow the Italian approach to funding independent clinical trials is unlikely to be a good idea.
In 2003, Italy decided to establish a tax on the drug industry of 5% of their medicines advertising budget. This money is used by the state medicines agency, AIFA, to fund clinical research on the efficacy of orphan drugs, comparisons of drugs for the same indication, observational outcome studies, and pharmacovigilance.1 2